Market Trends of Global Venous Stents Industry
This section covers the major market trends shaping the Venous Stents Market according to our research experts:
Chronic Deep Vein Thrombosis is expected to Dominate the Market Share
Chronic Deep Vein Thrombosis is a blood clot in one of the large, deep veins that returns blood from the leg, and very rarely in the arm, or heart. The Segment growth is driven by the increasing prevalence of chronic deep vein thrombosis and product launches by the key market players.
According to the study titled "Deep Vein Thrombosis" published in the National Library of Medicine in August 2021, DVT is estimated to have an annual incidence of 80 cases per 100,000 people, with a lower limb DVT prevalence of 1 case per 1000 people. More than 200,000 people in the US experience venous thrombosis every year; 50,000 of these instances are exacerbated by pulmonary embolism. Thus, the growing prevalence of deep vein thrombosis is expected to drive the segment growth over the forecast period.
According to the study titled "Contralateral deep-vein thrombosis in lliac vein stenting - Incidence, etiology, and prevention" published in the Indian Journal Vascular and Endovascular Surgery, Iliofemoral venous outflow blockage is now treated most frequently with stenting. It is used to treat severe cases of ulcer healing as well as symptoms of chronic pain and swelling in individuals with postthrombotic syndrome (PTS) that has been formed after a prior deep vein thrombosis (DVT).
Thus, all aforementioned factors expected to boost the market growtrh over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall venous stents market, throughout the forecast period. The largest share is mainly due to the presence of key players and their usage of advanced medical technologies to develop products. Furthermore, established healthcare infrastructure, and high investments for healthcare are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.
According to the Center for Diseases Control and Prevention in June 2022, Each year in the United States, 900,000 people may be impacted by deep vein thrombosis (DVT) or pulmonary embolism (PE). A DVT can result in long-term consequences (post-thrombotic syndrome), which include edoema, discomfort, discolouration, and scaling in the affected leg, in one-third to one-half of patients. Within 10 years, around one-third (about 33%) of patients with DVT/PE has experienced a recurrence.
The market players engage in the research and development activity expected to boost the market in the region. For instance, in December 2021, Vesper Medical has completed subject enrolment in the pivotal VIVID clinical trial of the Vesper Duo Venous Stent System. Additionally, in May 2021, in Canada, Endologix introduced the Alto Abdominal Stent Graft System. With the aid of cutting-edge endovascular aneurysm repair (EVAR) technology, the company expands its global reach.
Thus, all aforementioned factors expected to boost the segment growth in the region over the forecast period.
